Ligand Pharmaceuticals Inc (LGND) 49.08 $LGND
Ligand Pharmaceuticals Down 16.9% Since SmarTrend Downtrend Call (LGND)
Comtex SmarTrend(R) - Thu Jul 31, 11:16AM CDT
SmarTrend identified a Downtrend for Ligand Pharmaceuticals (NASDAQ:LGND) on June 24th, 2014 at $60.80. In approximately 1 month, Ligand Pharmaceuticals has returned 16.94% as of today's recent price of $50.50.
The Federal Reserve Playing Analyst Damaging to Biotechnology Companies
ACCESSWIRE - Wed Jul 30, 9:06AM CDT
WHITEFISH, MT / July 30, 2014 / The July 15 U.S. Federal Reserve report on monetary policy touched off a barrage of barely polite and not very muted commentary from one end of the web to the other this past week with 32 simple words: "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The release of the report to Congress coincided with the start of Federal Reserve Chairwoman Janet Yellen's testimony before a Congressional committee. NBI, the Nasdaq Biotechnology Index, slumped from around 2,700 on Tuesday to a low of 2,536 on Thursday, a 6% nosedive, before paring the losses with an up day on Friday. Of the 120 companies in the NBI, 101 closed in the red last week, including Ligand Pharma (NASDAQ: LGND) shedding 19.4% and Raptor Pharma (NASDAQ: RPTP) falling 18.7%.
Shares of LGND Down 14.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 24, 9:56AM CDT
SmarTrend identified a Downtrend for Ligand Pharmaceuticals (NASDAQ:LGND) on June 24th, 2014 at $60.80. In approximately 1 month, Ligand Pharmaceuticals has returned 14.69% as of today's recent price of $51.87.
4 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 24, 8:25AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
Ligand Partner GSK Announces Record Quarterly Promacta(TM)/Revolade(TM) Revenue of $92 Million
Business Wire - Wed Jul 23, 8:30AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner GlaxoSmithKline (GSK) plc has announced global revenue for Promacta(TM)/Revolade(TM) for the second quarter ended June 30, 2014 of $92 million, up 31% from the second quarter of 2013. United States, European Union and the Emerging Markets all reported double-digit growth over the prior quarter, with United States up 17% and Emerging Markets up 50% versus first quarter 2014.
Ligand Pharmaceuticals awarded US FDA's fast track designation for SAGE-547 development programme
M2 - Wed Jul 23, 6:47AM CDT
Ligand Pharmaceuticals (NasdaqGM:LGND) reported on Tuesday the receipt of the US Food and Drug Administration's (FDA) fast track designation for the SAGE-547 development programme.
Ligand Partner SAGE Therapeutics Receives Fast Track Designation for Captisol-enabled SAGE-547 to Treat Status Epilepticus
Business Wire - Tue Jul 22, 12:15PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Sage Therapeutics Inc., a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program. SAGE-547 is an allosteric modulator of GABAA receptors in development for the treatment of adult patients with refractory status epilepticus who have not responded to standard regimens (super-refractory status epilepticus, or SRSE).
Lemelson Capital Management Announces TTM and Second Quarter 2014 Performance Results for The Amvona Fund
PR Newswire - Thu Jul 17, 10:53AM CDT
Lemelson Capital Management, LLC, a private investment management firm, today announced performance results for its flagship Amvona Fund for the trailing 12 months (TTM) through June 30, 2014. During this period, the fund beat the benchmark S&P 500 Total Returns Index by 407.95 percent, returning 87.22 percent net of all fees and expenses. The fund's TTM performance was fueled in part by its significant short position in Ligand Pharmaceuticals (NASDAQ:LGND), a previous short position in World Wrestling Entertainment and its current long position in Kulicke & Soffa Industries.
Downtrend Call Working As Ligand Pharmaceuticals Stock Falls 10.6% (LGND)
Comtex SmarTrend(R) - Thu Jul 17, 9:28AM CDT
SmarTrend identified a Downtrend for Ligand Pharmaceuticals (NASDAQ:LGND) on June 24th, 2014 at $60.80. In approximately 3 weeks, Ligand Pharmaceuticals has returned 10.56% as of today's recent price of $54.38.
Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:31AM CDT
Ligand Pharmaceuticals has seen flat earnings estimate revisions for the current year along with a significant decline in its share price for the past month
Ligand Reports Second Quarter Revenues and Announces Share Repurchase Program
Business Wire - Thu Jul 17, 7:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that total revenues for the second quarter of 2014 are expected to be approximately $10.6 million. This exceeds guidance Ligand issued on May 7, 2014 for total revenues to be $9.0 million to $9.5 million. The incremental increase in revenue over previous guidance will result in additional earnings and cash-flow for the second quarter.
Ligand Chairman Dr. John W. Kozarich Named Director of the Year Honoree by Corporate Directors Forum
Business Wire - Mon Jul 14, 7:30AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that Chairman John W. Kozarich, Ph.D. has been named by Corporate Directors Forum as one of six Directors of the Year for 2014. Corporate Directors Forum (CDF) is a not-for-profit organization based in San Diego that was founded to promote high standards of professionalism in corporate governance. Each year CDF honors top directors for their outstanding performance in the boardroom for various categories. Dr. Kozarich will be honored at a program on September 23 as Honoree in the "Companies in Transition" category.
Technical Updates, License Agreements, and Acquisitions - Analyst Notes on Incyte, BioMarin, Arrowhead, Ligand and Techne
PR Newswire - Tue Jul 08, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Arrowhead Research Corp. (NASDAQ: ARWR), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Techne Corp. (NASDAQ: TECH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4525-100free.
Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Appends its LGND Research Report
PR Newswire - Mon Jul 07, 8:00AM CDT
Lemelson Capital Management, a private investment management firm, today announced that it has further increased its short position in Ligand Pharmaceuticals (NASDAQ: LGND) and appended with additional concerns its initial June 16, 2014 research report.
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jul 05, 2:00PM CDT
Fireworks weren't the only things skyrocketing this week. Several health-care stocks dazzled and popped also. One of this week's big winners gave a positively received update on a clinical trial. Another gained from a larger partner increasing its...
Insider Trading Alert - GPS, HCN And LGND Traded By Insiders
at The Street - Wed Jul 02, 10:30AM CDT
Stocks with insider trader activity include GPS, HCN and LGND
Patent Issuance, Positive Trial Data, Recognitions, and Priority Review - Analyst Notes on Keryx, Puma, Ligand, Sagent and Enanta
PR Newswire - Mon Jun 30, 6:50AM CDT
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Puma Biotechnology, Inc. (NYSE: PBYI), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4240-100free.
Glaxo's Promacta in Phase III for MDS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 1:30PM CDT
GlaxoSmithKline (GSK) has initiated a phase III study on Promacta plus Vidaza in patients suffering from myelodysplastic syndromes (MDS).
Ligand announces launch of Phase 3 Study of eltrombopag in myelodysplastic syndromes patients
M2 - Thu Jun 26, 5:09AM CDT
Biotechnology company Ligand Pharmaceuticals (NasdaqGM:LGND) Wednesday reported a Phase 3 study to evaluate the platelet supportive care effects of eltrombopag in intermediate-1, intermediate-2 or high-risk patients with myelodysplastic syndromes (MDS), a type of cancer in which the bone marrow does not make enough healthy blood cells.
Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 3:30PM CDT
Ligand Pharmaceuticals Inc. (LGND) inked a deal with TG Therapeutics, Inc. to develop and commercialize Ligand's IRAK-4 inhibitors.
Ligand Pharmaceuticals Down 16.9% Since SmarTrend Downtrend Call (LGND)
Comtex SmarTrend(R) - Thu Jul 31, 11:16AM CDT
SmarTrend identified a Downtrend for Ligand Pharmaceuticals (NASDAQ:LGND) on June 24th, 2014 at $60.80. In approximately 1 month, Ligand Pharmaceuticals has returned 16.94% as of today's recent price of $50.50.
The Federal Reserve Playing Analyst Damaging to Biotechnology Companies
ACCESSWIRE - Wed Jul 30, 9:06AM CDT
WHITEFISH, MT / July 30, 2014 / The July 15 U.S. Federal Reserve report on monetary policy touched off a barrage of barely polite and not very muted commentary from one end of the web to the other this past week with 32 simple words: "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The release of the report to Congress coincided with the start of Federal Reserve Chairwoman Janet Yellen's testimony before a Congressional committee. NBI, the Nasdaq Biotechnology Index, slumped from around 2,700 on Tuesday to a low of 2,536 on Thursday, a 6% nosedive, before paring the losses with an up day on Friday. Of the 120 companies in the NBI, 101 closed in the red last week, including Ligand Pharma (NASDAQ: LGND) shedding 19.4% and Raptor Pharma (NASDAQ: RPTP) falling 18.7%.
Shares of LGND Down 14.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 24, 9:56AM CDT
SmarTrend identified a Downtrend for Ligand Pharmaceuticals (NASDAQ:LGND) on June 24th, 2014 at $60.80. In approximately 1 month, Ligand Pharmaceuticals has returned 14.69% as of today's recent price of $51.87.
4 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 24, 8:25AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
Ligand Partner GSK Announces Record Quarterly Promacta(TM)/Revolade(TM) Revenue of $92 Million
Business Wire - Wed Jul 23, 8:30AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner GlaxoSmithKline (GSK) plc has announced global revenue for Promacta(TM)/Revolade(TM) for the second quarter ended June 30, 2014 of $92 million, up 31% from the second quarter of 2013. United States, European Union and the Emerging Markets all reported double-digit growth over the prior quarter, with United States up 17% and Emerging Markets up 50% versus first quarter 2014.
Ligand Pharmaceuticals awarded US FDA's fast track designation for SAGE-547 development programme
M2 - Wed Jul 23, 6:47AM CDT
Ligand Pharmaceuticals (NasdaqGM:LGND) reported on Tuesday the receipt of the US Food and Drug Administration's (FDA) fast track designation for the SAGE-547 development programme.
Ligand Partner SAGE Therapeutics Receives Fast Track Designation for Captisol-enabled SAGE-547 to Treat Status Epilepticus
Business Wire - Tue Jul 22, 12:15PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Sage Therapeutics Inc., a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program. SAGE-547 is an allosteric modulator of GABAA receptors in development for the treatment of adult patients with refractory status epilepticus who have not responded to standard regimens (super-refractory status epilepticus, or SRSE).
Lemelson Capital Management Announces TTM and Second Quarter 2014 Performance Results for The Amvona Fund
PR Newswire - Thu Jul 17, 10:53AM CDT
Lemelson Capital Management, LLC, a private investment management firm, today announced performance results for its flagship Amvona Fund for the trailing 12 months (TTM) through June 30, 2014. During this period, the fund beat the benchmark S&P 500 Total Returns Index by 407.95 percent, returning 87.22 percent net of all fees and expenses. The fund's TTM performance was fueled in part by its significant short position in Ligand Pharmaceuticals (NASDAQ:LGND), a previous short position in World Wrestling Entertainment and its current long position in Kulicke & Soffa Industries.
Downtrend Call Working As Ligand Pharmaceuticals Stock Falls 10.6% (LGND)
Comtex SmarTrend(R) - Thu Jul 17, 9:28AM CDT
SmarTrend identified a Downtrend for Ligand Pharmaceuticals (NASDAQ:LGND) on June 24th, 2014 at $60.80. In approximately 3 weeks, Ligand Pharmaceuticals has returned 10.56% as of today's recent price of $54.38.
Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:31AM CDT
Ligand Pharmaceuticals has seen flat earnings estimate revisions for the current year along with a significant decline in its share price for the past month
Ligand Reports Second Quarter Revenues and Announces Share Repurchase Program
Business Wire - Thu Jul 17, 7:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that total revenues for the second quarter of 2014 are expected to be approximately $10.6 million. This exceeds guidance Ligand issued on May 7, 2014 for total revenues to be $9.0 million to $9.5 million. The incremental increase in revenue over previous guidance will result in additional earnings and cash-flow for the second quarter.
Ligand Chairman Dr. John W. Kozarich Named Director of the Year Honoree by Corporate Directors Forum
Business Wire - Mon Jul 14, 7:30AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that Chairman John W. Kozarich, Ph.D. has been named by Corporate Directors Forum as one of six Directors of the Year for 2014. Corporate Directors Forum (CDF) is a not-for-profit organization based in San Diego that was founded to promote high standards of professionalism in corporate governance. Each year CDF honors top directors for their outstanding performance in the boardroom for various categories. Dr. Kozarich will be honored at a program on September 23 as Honoree in the "Companies in Transition" category.
Technical Updates, License Agreements, and Acquisitions - Analyst Notes on Incyte, BioMarin, Arrowhead, Ligand and Techne
PR Newswire - Tue Jul 08, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Arrowhead Research Corp. (NASDAQ: ARWR), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Techne Corp. (NASDAQ: TECH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4525-100free.
Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Appends its LGND Research Report
PR Newswire - Mon Jul 07, 8:00AM CDT
Lemelson Capital Management, a private investment management firm, today announced that it has further increased its short position in Ligand Pharmaceuticals (NASDAQ: LGND) and appended with additional concerns its initial June 16, 2014 research report.
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jul 05, 2:00PM CDT
Fireworks weren't the only things skyrocketing this week. Several health-care stocks dazzled and popped also. One of this week's big winners gave a positively received update on a clinical trial. Another gained from a larger partner increasing its...
Insider Trading Alert - GPS, HCN And LGND Traded By Insiders
at The Street - Wed Jul 02, 10:30AM CDT
Stocks with insider trader activity include GPS, HCN and LGND
Patent Issuance, Positive Trial Data, Recognitions, and Priority Review - Analyst Notes on Keryx, Puma, Ligand, Sagent and Enanta
PR Newswire - Mon Jun 30, 6:50AM CDT
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Puma Biotechnology, Inc. (NYSE: PBYI), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4240-100free.
Glaxo's Promacta in Phase III for MDS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 1:30PM CDT
GlaxoSmithKline (GSK) has initiated a phase III study on Promacta plus Vidaza in patients suffering from myelodysplastic syndromes (MDS).
Ligand announces launch of Phase 3 Study of eltrombopag in myelodysplastic syndromes patients
M2 - Thu Jun 26, 5:09AM CDT
Biotechnology company Ligand Pharmaceuticals (NasdaqGM:LGND) Wednesday reported a Phase 3 study to evaluate the platelet supportive care effects of eltrombopag in intermediate-1, intermediate-2 or high-risk patients with myelodysplastic syndromes (MDS), a type of cancer in which the bone marrow does not make enough healthy blood cells.
Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 3:30PM CDT
Ligand Pharmaceuticals Inc. (LGND) inked a deal with TG Therapeutics, Inc. to develop and commercialize Ligand's IRAK-4 inhibitors.
